Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to “Hold” at Zacks Research

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

A number of other research firms also recently weighed in on EPRX. Cantor Fitzgerald raised their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. William Blair started coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Trading Down 0.3%

EPRX stock opened at $7.45 on Thursday. Eupraxia Pharmaceuticals has a 1-year low of $3.67 and a 1-year high of $9.32. The stock has a market cap of $450.20 million, a price-to-earnings ratio of -7.23 and a beta of 1.19. The company’s 50 day moving average is $7.38 and its 200 day moving average is $7.22.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). As a group, sell-side analysts forecast that Eupraxia Pharmaceuticals will post -0.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth $71,000. Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares in the last quarter. Guardian Wealth Advisors LLC NC purchased a new stake in Eupraxia Pharmaceuticals during the 4th quarter valued at approximately $76,000. Aptus Capital Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $76,000. Finally, Geode Capital Management LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth $105,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.